DEA Reschedules Marijuana to Schedule III; Implications for Canopy Growth
The DEA rescheduled marijuana from Schedule I to Schedule III, a change that primarily affects medical cannabis. This shift allows companies selling medical products to deduct standard business expenses under the IRS, offering financial relief but not immediate market impact. The reform is expected to benefit certain cannabis firms like Canopy Growth (CGC), though limitations on U.S. exports remain.
Tickers: $CGC